ArticleDiagnostics (Basel, Switzerland)2023
Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors.
Article in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Computational methods, clinical evidence, and translational readiness for artificial intelligence for HER2 assessment using silver in situ hybridization (SISH).Breast cancer research : BCR · 2026Pooled it
- Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 and Tumor Microenvironment Analysis in Human Epidermal Growth Factor Receptor 2-Amplified Metastatic Colorectal Cancer: Exploratory Analysis of Phase II TRIUMPH Trial.JCO precision oncology · 2025Trial
- Antibody-Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions.MedComm · 2026Review
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.World journal of oncology · 2026Review
- "HER2-Low" and the Challenge of Repurposing Legacy HER2 IHC Biomarker Assays.Current oncology (Toronto, Ont.) · 2026Article
- AI-enhanced precision: boosting pathologist confidence in HER2 ultra-low diagnosis through intelligent re-screening.Breast cancer research : BCR · 2026Article
- Artificial intelligence in immunotherapy: revolutionizing diagnostic and therapeutic applications in cancer and autoimmune diseases.Clinical and experimental medicine · 2026Review
- Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-Null to HER2-low, including HER2-ultralow status.Virchows Archiv : an international journal of pathology · 2026Article
- Improving HER2 Diagnostics with Digital Real-Time PCR for Ultrafast, Precise Prediction of Anti-HER2 Therapy Response in Patients with Breast Cancer.Small methods · 2026Article
- HER2-Ultralow: Prevalence, Characteristics, and Treatment Choices Among Advanced Breast Cancer Patients With Tumors Initially Scored as IHC 0.The breast journal · 2026Article
- Artificial Intelligence as an Assistive Tool in Breast Cancer Screening and Diagnosis in the Digital Era.International journal of breast cancer · 2026Article
- Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excision.NPJ breast cancer · 2025Article
- Quantification of HER2-low and ultra-low expression in breast cancer specimens by quantitative IHC and artificial intelligence.Journal of pathology informatics · 2025Article
- Kazakhstani HER2 breast cancer digital image dataset: The ADEL dataset.Data in brief · 2025Article
- Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence.Breast cancer research and treatment · 2025Article
- The SRG rat as a novel host for an orthotopic patient-derived xenograft model of breast cancer brain metastasis.Scientific reports · 2025Article
- Systematic review and meta-analysis of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry.NPJ digital medicine · 2025Article
- Digital counting of tissue cells for molecular analysis: the QuANTUM pipeline.Virchows Archiv : an international journal of pathology · 2025Article
- Interobserver consistency and diagnostic challenges in HER2-ultralow breast cancer: a multicenter study.ESMO open · 2025Article
- Reply to Graña et al. Comment on "Uzun Ozsahin et al. COVID-19 Prediction Using Black-Box Based Pearson Correlation Approach.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression of human epidermal growth factor receptor 2 (HER2) protein or gene transcripts is critical for therapeutic decision making in breast cancer. We examined the performance of a digitalized and artificial intelligence (AI)-assisted workflow for HER2 status determination in accordance with the American Society of Clinical Oncology (ASCO)/College of Pathologists (CAP) guidelines. Our preliminary cohort consisted of 495 primary breast carcinomas, and our study cohort included 67 primary breast carcinomas and 30 metastatic deposits, which were evaluated for HER2 status by immunohistochemistry (IHC) and in situ hybridization (ISH). Three practicing breast pathologists independently assessed and scored slides, building the ground truth. Following a washout period, pathologists were provided with the results of the AI digital image analysis (DIA) and asked to reassess the slides. Both rounds of assessment from the pathologists were compared to the AI results and ground truth for each slide. We observed an overall HER2 positivity rate of 15% in our study cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.